In 2003, results of the Valsartan in Acute Myocardial Infarction Trial (VALIANT) [39] found no significant differences between an ARB and an ACE inhibitor in all-cause mortality or major cardiovascular events among patients with myocardial infarction complicated by congestive heart failure and/or evidence of left ventricular systolic dysfunction. Here, ACE is linked to acute myocardial infarction.